Podcasts about ASCI

Funding for the NIH and US biomedical research is imperiled at a momentous time of progress. Exemplifying this is the work of Dr. Anna Greka, a leading physician-scientist at the Broad Institute who is devoted to unlocking the mysteries of rare diseases— that cumulatively affect 30 million Americans— and finding cures, science supported by the NIH.A clip from our conversationThe audio is available on iTunes and Spotify. The full video is linked here, at the top, and also can be found on YouTube.Transcript with audio and external linksEric Topol (00:06):Well, hello. This is Eric Topol from Ground Truths, and I am really delighted to welcome today, Anna Greka. Anna is the president of the American Society for Clinical Investigation (ASCI) this year, a very prestigious organization, but she's also at Mass General Brigham, a nephrologist, a cell biologist, a physician-scientist, a Core Institute Member of the Broad Institute of MIT and Harvard, and serves as a member of the institute's Executive Leadership Team. So we got a lot to talk about of all these different things you do. You must be pretty darn unique, Anna, because I don't know any cell biologists, nephrologists, physician-scientist like you.Anna Greka (00:48):Oh, thank you. It's a great honor to be here and glad to chat with you, Eric.Eric Topol (00:54):Yeah. Well, I had the real pleasure to hear you speak at a November conference, the AI for Science Forum, which we'll link to your panel. Where I was in a different panel, but you spoke about your extraordinary work and it became clear that we need to get you on Ground Truths, so you can tell your story to everybody. So I thought rather than kind of going back from the past where you were in Greece and somehow migrated to Boston and all that. We're going to get to that, but you gave an amazing TED Talk and it really encapsulated one of the many phenomenal stories of your work as a molecular sleuth. So maybe if you could give us a synopsis, and of course we'll link to that so people could watch the whole talk. But I think that Mucin-1 or MUC1, as you call it, discovery is really important to kind of ground our discussion.A Mysterious Kidney Disease Unraveled Anna Greka (01:59):Oh, absolutely. Yeah, it's an interesting story. In some ways, in my TED Talk, I highlight one of the important families of this story, a family from Utah, but there's also other important families that are also part of the story. And this is also what I spoke about in London when we were together, and this is really sort of a medical mystery that initially started on the Mediterranean island of Cyprus, where it was found that there were many families in which in every generation, several members suffered and ultimately died from what at the time was a mysterious kidney disease. This was more than 30 years ago, and it was clear that there was something genetic going on, but it was impossible to identify the gene. And then even with the advent of Next-Gen sequencing, this is what's so interesting about this story, it was still hard to find the gene, which is a little surprising.Anna Greka (02:51):After we were able to sequence families and identify monogenic mutations pretty readily, this was still very resistant. And then it actually took the firepower of the Broad Institute, and it's actually from a scientific perspective, an interesting story because they had to dust off the old-fashioned Sanger sequencing in order to get this done. But they were ultimately able to identify this mutation in a VNTR region of the MUC1 gene. The Mucin-1 gene, which I call a dark corner of the human genome, it was really, it's highly repetitive, very GC-rich. So it becomes very difficult to sequence through there with Next-Gen sequencing. And so, ultimately the mutation of course was found and it's a single cytosine insertion in a stretch of cytosines that sort of causes this frameshift mutation and an early stop codon that essentially results in a neoprotein like a toxic, what I call a mangled protein that sort of accumulates inside the kidney cells.Anna Greka (03:55):And that's where my sort of adventure began. It was Eric Lander's group, who is the founding director of the Broad who discovered the mutation. And then through a conversation we had here in Boston, we sort of discovered that there was an opportunity to collaborate and so that's how I came to the Broad, and that's the beginnings of this story. I think what's fascinating about this story though, that starts in a remote Mediterranean island and then turns out to be a disease that you can find in every continent all over the world. There are probably millions of patients with kidney disease in whom we haven't recognized the existence of this mutation. What's really interesting about it though is that what we discovered is that the mangled protein that's a result of this misspelling of this mutation is ultimately captured by a family of cargo receptors, they're called the TMED cargo receptors and they end up sort of grabbing these misfolded proteins and holding onto them so tight that it's impossible for the cell to get rid of them.Anna Greka (04:55):And they become this growing heap of molecular trash, if you will, that becomes really hard to manage, and the cells ultimately die. So in the process of doing this molecular sleuthing, as I call it, we actually also identified a small molecule that actually disrupts these cargo receptors. And as I described in my TED Talk, it's a little bit like having these cargo trucks that ultimately need to go into the lysosome, the cells recycling facility. And this is exactly what this small molecule can do. And so, it was just like a remarkable story of discovery. And then I think the most exciting of all is that these cargo receptors turn out to be not only relevant to this one mangled misshapen protein, but they actually handle a completely different misshapen protein caused by a different genetic mutation in the eye, causing retinitis pigmentosa, a form of blindness, familial blindness. We're now studying familial Alzheimer's disease that's also involving these cargo receptors, and there are other mangled misshapen proteins in the liver, in the lung that we're now studying. So this becomes what I call a node, like a nodal mechanism that can be targeted for the benefit of many more patients than we had previously thought possible, which has been I think, the most satisfying part about this story of molecular sleuthing.Eric Topol (06:20):Yeah, and it's pretty extraordinary. We'll put the figure from your classic Cell paper in 2019, where you have a small molecule that targets the cargo receptor called TMED9.Anna Greka (06:34):Correct.Expanding the MissionEric Topol (06:34):And what's amazing about this, of course, is the potential to reverse this toxic protein disease. And as you say, it may have applicability well beyond this MUC1 kidney story, but rather eye disease with retinitis pigmentosa and the familial Alzheimer's and who knows what else. And what's also fascinating about this is how, as you said, there were these limited number of families with the kidney disease and then you found another one, uromodulin. So there's now, as you say, thousands of families, and that gets me to part of your sleuth work is not just hardcore science. You started an entity called the Ladders to Cures (L2C) Scientific Accelerator.Eric Topol (07:27):Maybe you can tell us about that because this is really pulling together all the forces, which includes the patient advocacy groups, and how are we going to move forward like this?Anna Greka (07:39):Absolutely. I think the goal of the Ladders to Cures Accelerator, which is a new initiative that we started at the Broad, but it really encompasses many colleagues across Boston. And now increasingly it's becoming sort of a national, we even have some international collaborations, and it's only two years that it's been in existence, so we're certainly in a growth mode. But the inspiration was really some of this molecular sleuthing work where I basically thought, well, for starters, it cannot be that there's only one molecular node, these TMED cargo receptors that we discovered there's got to be more, right? And so, there's a need to systematically go and find more nodes because obviously as anyone who works in rare genetic diseases will tell you, the problem for all of us is that we do what I call hand to hand combat. We start with the disease with one mutation, and we try to uncover the mechanism and then try to develop therapies, and that's wonderful.Anna Greka (08:33):But of course, it's slow, right? And if we consider the fact that there are 30 million patients in the United States in every state, everywhere in the country who suffer from a rare genetic disease, most of them, more than half of them are children, then we can appreciate the magnitude of the problem. Out of more than 8,000 genes that are involved in rare genetic diseases, we barely have something that looks like a therapy for maybe 500 of them. So there's a huge mismatch in the unmet need and magnitude of the problem. So the Ladders to Cures Accelerator is here to address this and to do this with the most modern tools available. And to your point, Eric, to bring patients along, not just as the recipients of whatever we discover, but also as partners in the research enterprise because it's really important to bring their perspectives and of course their partnerships in things like developing appropriate biomarkers, for example, for what we do down the road.Anna Greka (09:35):But from a fundamental scientific perspective, this is basically a project that aims to identify every opportunity for nodes, underlying all rare genetic diseases as quickly as possible. And this was one of the reasons I was there at the AI for Science Forum, because of course when one undertakes a project in which you're basically, this is what we're trying to do in the Ladders to Cures Accelerator, introduce dozens of thousands of missense and nonsense human mutations that cause genetic diseases, simultaneously introduce them into multiple human cells and then use modern scalable technology tools. Things like CRISPR screens, massively parallel CRISPR screens to try to interrogate all of these diseases in parallel, identify the nodes, and then develop of course therapeutic programs based on the discovery of these nodes. This is a massive data generation project that is much needed and in addition to the fact that it will help hopefully accelerate our approach to all rare diseases, genetic diseases. It is also a highly controlled cell perturbation dataset that will require the most modern tools in AI, not only to extract the data and understand the data of this dataset, but also because this, again, an extremely controlled, well controlled cell perturbation dataset can be used to train models, train AI models, so that in the future, and I hope this doesn't sound too futuristic, but I think that we're all aiming for that cell biologists for sure dream of this moment, I think when we can actually have in silico the opportunity to make predictions about what cell behaviors are going to look like based on a new perturbation that was not in the training set. So an experiment that hasn't yet been done on a cell, a perturbation that has not been made on a human cell, what if like a new drug, for example, or a new kind of perturbation, a new chemical perturbation, how would it affect the behavior of the cell? Can we make a predictive model for that? This doesn't exist today, but I think this is something, the cell prediction model is a big question for biology for the future. And so, I'm very energized by the opportunity to both address this problem of rare monogenic diseases that remains an unmet need and help as many patients as possible while at the same time advancing biology as much as we possibly can. So it's kind of like a win-win lifting all boats type of enterprise, hopefully.Eric Topol (12:11):Yeah. Well, there's many things to get to unpack what you've just been reviewing. So one thing for sure is that of these 8,000 monogenic diseases, they have relevance to the polygenic common diseases, of course. And then also the fact that the patient family advocates, they are great at scouring the world internet, finding more people, bringing together communities for each of these, as you point out aptly, these rare diseases cumulatively are high, very high proportion, 10% of Americans or more. So they're not so rare when you think about the overall.Anna Greka (12:52):Collectively.Help From the Virtual Cell?Eric Topol (12:53):Yeah. Now, and of course is this toxic proteinopathies, there's at least 50 of these and the point that people have been thinking until now that, oh, we found a mangled protein, but what you've zeroed in on is that, hey, you know what, it's not just a mangled protein, it's how it gets stuck in the cell and that it can't get to the lysosome to get rid of it, there's no waste system. And so, this is such fundamental work. Now that gets me to the virtual cell story, kind of what you're getting into. I just had a conversation with Charlotte Bunne and Steve Quake who published a paper in December on the virtual cell, and of course that's many years off, but of course it's a big, bold, ambitious project to be able to say, as you just summarized, if you had cells in silico and you could do perturbations in silico, and of course they were validated by actual experiments or bidirectionally the experiments, the real ones helped to validate the virtual cell, but then you could get a true acceleration of your understanding of cell biology, your field of course.Anna Greka (14:09):Exactly.Eric Topol (14:12):So what you described, is it the same as a virtual cell? Is it kind of a precursor to it? How do you conceive this because this is such a complex, I mean it's a fundamental unit of life, but it's also so much more complex than a protein or an RNA because not only all the things inside the cell, inside all these organelles and nucleus, but then there's all the outside interactions. So this is a bold challenge, right?Anna Greka (14:41):Oh my god, it's absolutely from a biologist perspective, it's the challenge of a generation for sure. We think taking humans to Mars, I mean that's an aspirational sort of big ambitious goal. I think this is the, if you will, the Mars shot for biology, being able to, whether the terminology, whether you call it a virtual cell. I like the idea of saying that to state it as a problem, the way that people who think about it from a mathematics perspective for example, would think about it. I think stating it as the cell prediction problem appeals to me because it actually forces us biologists to think about setting up the way that we would do these cell perturbation data sets, the way we would generate them to set them up to serve predictions. So for example, the way that I would think about this would be can I in the future have so much information about how cell perturbations work that I can train a model so that it can predict when I show it a picture of another cell under different conditions that it hasn't seen before, that it can still tell me, ah, this is a neuron in which you perturbed the mitochondria, for example, and now this is sort of the outcome that you would expect to see.Anna Greka (16:08):And so, to be able to have this ability to have a model that can have the ability to predict in silico what cells would look like after perturbation, I think that's sort of the way that I think about this problem. It is very far away from anything that exists today. But I think that the beginning starts, and this is one of the unique things about my institute, if I can say, we have a place where cell biologists, geneticists, mathematicians, machine learning experts, we all come together in the same place to really think and grapple with these problems. And of course we're very outward facing, interacting with scientists all across the world as well. But there's this sort of idea of bringing people into one institute where we can just think creatively about these big aspirational problems that we want to solve. I think this is one of the unique things about the ecosystem at the Broad Institute, which I'm proud to be a part of, and it is this kind of out of the box thinking that will hopefully get us to generate the kinds of data sets that will serve the needs of building these kinds of models with predictive capabilities down the road.Anna Greka (17:19):But as you astutely said, AlphaFold of course was based on the protein database existing, right? And that was a wealth of available information in which one could train models that would ultimately be predictive, as we have seen this miracle that Demi Hassabis and John Jumper have given to humanity, if you will.Anna Greka (17:42):But as Demis and John would also say, I believe is as I have discussed with them, in fact, the cell prediction problem is really a bigger problem because we do not have a protein data bank to go to right now, but we need to create it to generate these data. And so, my Ladders to Cures Accelerator is here to basically provide some part of the answer to that problem, create this kind of well-controlled database that we need for cell perturbations, while at the same time maximizing our learnings about these fully penetrant coding mutations and what their downstream sequelae would be in many different human cells. And so, in this way, I think we can both advance our knowledge about these monogenic diseases, build models, hopefully with predictive capabilities. And to your point, a lot of what we will learn about this biology, if we think that it involves 8,000 or more out of the 20,000 genes in our genome, it will of course serve our understanding of polygenic diseases ultimately as well as we go deeper into this biology and we look at the combinatorial aspects of what different mutations do to human cells. And so, it's a huge aspirational problem for a whole generation, but it's a good one to work on, I would say.Learning the Language of Life with A.I. Eric Topol (19:01):Oh, absolutely. Now I think you already mentioned something that's quite, well, two things from what you just touched on. One of course, how vital it is to have this inner or transdisciplinary capability because you do need expertise across these vital areas. But the convergence, I mean, I love your term nodal biology and the fact that there's all these diseases like you were talking about, they do converge and nodal is a good term to highlight that, but it's not. Of course, as you mentioned, we have genome editing which allows to look at lots of different genome perturbations, like the single letter change that you found in MUC1 pathogenic critical mutation. There's also the AI world which is blossoming like I've never seen. In fact, I had in Science this week about learning the language of life with AI and how there's been like 15 new foundation models, DNA, proteins, RNA, ligands, all their interactions and the beginning of the cell story too with the human cell.Eric Topol (20:14):So this is exploding. As you said, the expertise in computer science and then this whole idea that you could take these powerful tools and do as you said, which is the need to accelerate, we just can't sit around here when there's so much discovery work to be done with the scalability, even though it might take years to get to this artificial intelligence virtual cell, which I have to agree, everyone in biology would say that's the holy grail. And as you remember at our conference in London, Demi Hassabis said that's what we'd like to do now. So it has the attention of leaders in AI around the world, obviously in the science and the biomedical community like you and many others. So it is an extraordinary time where we just can't sit still with these tools that we have, right?Anna Greka (21:15):Absolutely. And I think this is going to be, you mentioned the ASCI presidency in the beginning of our call. This is going to be the president gets to give an address at the annual meeting in Chicago. This is going to be one of the points I make, no matter what field in biomedicine we're in, we live in, I believe, a golden era and we have so many tools available to us that we can really accelerate our ability to help more patients. And of course, this is our mandate, the most important stakeholders for everything that we do as physician-scientists are our patients ultimately. So I feel very hopeful for the future and our ability to use these tools and to really make good on the promise of research is a public good. And I really hope that we can advance our knowledge for the benefit of all. And this is really an exciting time, I think, to be in this field and hopefully for the younger colleagues a time to really get excited about getting in there and getting involved and asking the big questions.Career ReflectionsEric Topol (22:21):Well, you are the prototype for this and an inspiration to everyone really, I'm sure to your lab group, which you highlighted in the TED Talk and many other things that you do. Now I want to spend a little bit of time about your career. I think it's fascinating that you grew up in Greece and your father's a nephrologist and your mother's a pathologist. So you had two physicians to model, but I guess you decided to go after nephrology, which is an area in medicine that I kind of liken it to Rodney Dangerfield, he doesn't get any respect. You don't see many people that go into nephrology. But before we get to your decision to do that somehow or other you came from Greece to Harvard for your undergrad. How did you make that connect to start your college education? And then subsequently you of course you stayed in Boston, you've never left Boston, I think.Anna Greka (23:24):I never left. Yeah, this is coming into 31 years now in Boston.Anna Greka (23:29):Yeah, I started as a Harvard undergraduate and I'm now a full professor. It's kind of a long, but wonderful road. Well, actually I would credit my parents. You mentioned that my father, they're both physician-scientists. My father is now both retired, but my father is a nephrologist, and my mother is a pathologist, actually, they were both academics. And so, when we were very young, we lived in England when my parents were doing postdoctoral work. That was actually a wonderful gift that they gave me because I became bilingual. It was a very young age, and so that allowed me to have this advantage of being fluent in English. And then when we moved back to Greece where I grew up, I went to an American school. And from that time, this is actually an interesting story in itself. I'm very proud of this school.Anna Greka (24:22):It's called Anatolia, and it was founded by American missionaries from Williams College a long time ago, 150 and more years ago. But it is in Thessaloniki, Greece, which is my hometown, and it's a wonderful institution, which gave me a lot of gifts as well, preparing me for coming to college in the United States. And of course, I was a good student in high school, but what really was catalytic was that I was lucky enough to get a scholarship to go to Harvard. And that was really, you could say the catalyst that propelled me from a teenager who was dreaming about a career as a physician-scientist because I certainly was for as far back as I remember in fact. But then to make that a reality, I found myself on the Harvard campus initially for college, and then I was in the combined Harvard-MIT program for my MD PhD. And then I trained in Boston at Mass General in Brigham, and then sort of started my academic career. And that sort of brings us to today, but it is an unlikely story and one that I feel still very lucky and blessed to have had these opportunities. So for sure, it's been wonderful.Eric Topol (25:35):We're the ones lucky that you came here and set up shop and you did your productivity and discovery work and sleuthing has been incredible. But I do think it's interesting too, because when you did your PhD, it was in neuroscience.Anna Greka (25:52):Ah, yes. That's another.Eric Topol (25:54):And then you switch gears. So tell us about that?Anna Greka (25:57):This is interesting, and actually I encourage more colleagues to think about it this way. So I have always been driven by the science, and I think that it seems a little backward to some people, but I did my PhD in neuroscience because I was interested in understanding something about these ion channels that were newly discovered at the time, and they were most highly expressed in the brain. So here I was doing work in the brain in the neuroscience program at Harvard, but then once I completed my PhD and I was in the middle of my residency training actually at Mass General, I distinctly remember that there was a paper that came out that implicated the same family of ion channels that I had spent my time understanding in the brain. It turned out to be a channelopathy that causes kidney disease.Anna Greka (26:43):So that was the light bulb, and it made me realize that maybe what I really wanted to do is just follow this thread. And my scientific curiosity basically led me into studying the kidney and then it seemed practical therefore to get done with my clinical training as efficiently as possible. So I finished residency, I did nephrology training, and then there I was in the lab trying to understand the biology around this channelopathy. And that sort of led us into the early projects in my young lab. And in fact, it's interesting we didn't talk about that work, but that work in itself actually has made it all the way to phase II trials in patients. This was a paper we published in Science in 2017 and follow onto that work, there was an opportunity to build this into a real drug targeting one of these ion channels that has made it into phase II trials. And we'll see what happens next. But it's this idea of following your scientific curiosity, which I also talked about in my TED Talk, because you don't know to what wonderful places it will lead you. And quite interestingly now my lab is back into studying familial Alzheimer's and retinitis pigmentosa in the eye in brain. So I tell people, do not limit yourself to whatever someone says your field is or should be. Just follow your scientific curiosity and usually that takes you to a lot more interesting places. And so, that's certainly been a theme from my career, I would say.Eric Topol (28:14):No, I think that's perfect. Curiosity driven science is not the term. You often hear hypothesis driven or now with AI you hear more AI exploratory science. But no, that's great. Now I want to get a little back to the AI story because it's so fascinating. You use lots of different types of AI such as cellular imaging would be fusion models and drug discovery. I mean, you've had drug discovery for different pathways. You mentioned of course the ion channel and then also as we touched on with your Cell paper, the whole idea of targeting the cargo receptor with a small molecule and then things in between. You discussed this of course at the London panel, but maybe you just give us the skinny on the different ways that you incorporate AI in the state-of-the-art science that you're doing?Anna Greka (29:17):Sure, yeah, thank you. I think there are many ways in which even for quite a long time before AI became such a well-known kind of household term, if you will, the concept of machine learning in terms of image processing is something that has been around for some time. And so, this is actually a form of AI that we use in order to process millions of images. My lab has by produced probably more than 20 million images over the last few years, maybe five to six years. And so, if you can imagine it's impossible for any human to process this many images and make sense of them. So of course, we've been using machine learning that is becoming increasingly more and more sophisticated and advanced in terms of being able to do analysis of images, which is a lot of what we cell biologists do, of course.Anna Greka (30:06):And so, there's multiple different kinds of perturbations that we do to cells, whether we're using CRISPR or base editing to make, for example, genome wide or genome scale perturbations or small molecules as we have done as well in the past. These are all ways in which we are then using machine learning to read out the effects in images of cells that we're looking at. So that's one way in which machine learning is used in our daily work, of course, because we study misshape and mangled proteins and how they are recognized by these cargo receptors. We also use AlphaFold pretty much every day in my lab. And this has been catalytic for us as a tool because we really are able to accelerate our discoveries in ways that were even just three or four years ago, completely impossible. So it's been incredible to see how the young people in my lab are just so excited to use these tools and they're becoming extremely savvy in using these tools.Anna Greka (31:06):Of course, this is a new generation of scientists, and so we use AlphaFold all the time. And this also has a lot of implications of course for some of the interventions that we might think about. So where in this cargo receptor complex that we study for example, might we be able to fit a drug that would disrupt the complex and lead the cargo tracks into the lysosome for degradation, for example. So there's many ways in which AI can be used for all of these functions. So I would say that if we were to organize our thinking around it, one way to think about the use of machine learning AI is around what I would call understanding biology in cells and what in sort of more kind of drug discovery terms you would call target identification, trying to understand the things that we might want to intervene on in order to have a benefit for disease.Anna Greka (31:59):So target ID is one area in which I think machine learning and AI will have a catalytic effect as they already are. The other of course, is in the actual development of the appropriate drugs in a rational way. So rational drug design is incredibly enabled by AlphaFold and all these advances in terms of understanding protein structures and how to fit drugs into them of all different modalities and kinds. And I think an area that we are not yet harnessing in my group, but I think the Ladders to Cures Accelerator hopes to build on is really patient data. I think that there's a lot of opportunity for AI to be used to make sense of medical records for example and how we extract information that would tell us that this cohort of patients is a better cohort to enroll in your trial versus another. There are many ways in which we can make use of these tools. Not all of them are there yet, but I think it's an exciting time for being involved in this kind of work.Eric Topol (32:58):Oh, no question. Now it must be tough when you know the mechanism of these families disease and you even have a drug candidate, but that it takes so long to go from that to helping these families. And what are your thoughts about that, I mean, are you thinking also about genome editing for some of these diseases or are you thinking to go through the route of here's a small molecule, here's the tox data in animal models and here's phase I and on and on. Where do you think because when you know so much and then these people are suffering, how do you bridge that gap?Anna Greka (33:39):Yeah, I think that's an excellent question. Of course, having patients as our partners in our research is incredible as a way for us to understand the disease, to build biomarkers, but it is also exactly creating this kind of emotional conflict, if you will, because of course, to me, honesty is the best policy, if you will. And so, I'm always very honest with patients and their families. I welcome them to the lab so they can see just how long it takes to get some of these things done. Even today with all the tools that we have, of course there are certain things that are still quite slow to do. And even if you have a perfect drug that looks like it fits into the right pocket, there may still be some toxicity, there may be other setbacks. And so, I try to be very honest with patients about the road that we're on. The small molecule path for the toxic proteinopathies is on its way now.Anna Greka (34:34):It's partnered with a pharmaceutical company, so it's on its way hopefully to patients. Of course, again, this is an unpredictable road. Things can happen as you very well know, but I'm at least glad that it's sort of making its way there. But to your point, and I'm in an institute where CRISPR was discovered, and base editing and prime editing were discovered by my colleagues here. So we are in fact looking at every other modality that could help with these diseases. We have several hurdles to overcome because in contrast to the liver and the brain, the kidney for example, is not an organ in which you can easily deliver nucleic acid therapies, but we're making progress. I have a whole subgroup within the bigger group who's focusing on this. It's actually organized in a way where they're running kind of independently from the cell biology group that I run.Anna Greka (35:31):And it's headed by a person who came from industry so that she has the opportunity to really drive the project the way that it would be run milestone driven, if you will, in a way that it would be run as a therapeutics program. And we're really trying to go after all kinds of different nucleic acid therapies that would target the mutations themselves rather than the cargo receptors. And so, there's ASO and siRNA technologies and then also actual gene editing technologies that we are investigating. But I would say that some of them are closer than others. And again, to your question about patients, I tell them honestly when a project looks to be more promising, and I also tell them when a project looks to have hurdles and that it will take long and that sometimes I just don't know how long it will take before we can get there. The only thing that I can promise patients in any of our projects, whether it's Alzheimer's, blindness, kidney disease, all I can promise is that we're working the hardest we possibly can on the problem.Anna Greka (36:34):And I think that is often reassuring I have found to patients, and it's best to be honest about the fact that these things take a long time, but I do think that they find it reassuring that someone is on it essentially, and that there will be some progress as we move forward. And we've made progress in the very first discovery that came out of my lab. As I mentioned to you, we've made it all the way to phase II trials. So I have seen the trajectory be realized, and I'm eager to make it happen again and again as many times as I can within my career to help as many people as possible.The Paucity of Physician-ScientistsEric Topol (37:13):I have no doubts that you'll be doing this many times in your career. No, there's no question about it. It's extraordinary actually. There's a couple of things there I want to pick up on. Physician-scientists, as you know, are a rarefied species. And you have actually so nicely told the story about when you have a physician-scientist, you're caring for the patients that you're researching, which is, most of the time we have scientists. Nothing wrong with them of course, but you have this hinge point, which is really important because you're really hearing the stories and experiencing the patients and as you say, communicating about the likelihood of being able to come up with a treatment or the progress. What are we going to do to get more physician-scientists? Because this is a huge problem, it has been for decades, but the numbers just keep going lower and lower.Anna Greka (38:15):I think you're absolutely right. And this is again, something that in my leadership of the ASCI I have made sort of a cornerstone of our efforts. I think that it has been well-documented as a problem. I think that the pressures of modern clinical care are really antithetical to the needs of research, protected time to really be able to think and be creative and even have the funding available to be able to pursue one's program. I think those pressures are becoming so heavy for investigators that many of them kind of choose one or the other route most often the clinical route because that tends to be, of course where they can support their families better. And so, this has been kind of the conundrum in some ways that we take our best and brightest medical students who are interested in investigation, we train them and invest in them in becoming physician-scientists, but then we sort of drop them at the most vulnerable time, which is usually after one completes their clinical and scientific training.Anna Greka (39:24):And they're embarking on early phases of one's careers. It has been found to be a very vulnerable point when a lot of people are now in their mid-thirties or even late thirties perhaps with some family to take care of other burdens of adulthood, if you will. And I think what it becomes very difficult to sustain a career where one salary is very limited due to the research component. And so, I think we have to invest in our youngest people, and it is a real issue that there's no good mechanism to do that at the present time. So I was actually really hoping that there would be an opportunity with leadership at the NIH to really think about this. It's also been discussed at the level of the National Academy of Medicine where I had some role in discussing the recent report that they put out on the biomedical enterprise in the United States. And it's kind of interesting to see that there is a note made there about this issue and the fact that there needs to be, I think, more generous investment in the careers of a few select physician-scientists that we can support. So if you look at the numbers, currently out of the entire physician workforce, a physician-scientist comprised of less than 1%.Anna Greka (40:45):It's probably closer to 0.8% at this point.Eric Topol (40:46):No, it's incredible.Anna Greka (40:48):So that's really not enough, I think, to maintain the enterprise and if you will, this incredible innovation economy that the United States has had this miracle engine, if you will, in biomedicine that has been fueled in large part by physician investigators. Of course, our colleagues who are non-physician investigators are equally important partners in this journey. But we do need a few of the physician-scientists investigators I think as well, if you really think about the fact that I think 70% of people who run R&D programs in all the big pharmaceutical companies are physician-scientists. And so, we need people like us to be able to work on these big problems. And so, more investment, I think that the government, the NIH has a role to play there of course. And this is important from both an economic perspective, a competition perspective with other nations around the world who are actually heavily investing in the physician-scientist workforce.Anna Greka (41:51):And I think it's also important to do so through our smaller scale efforts at the ASCI. So one of the things that I have been involved in as a council member and now as president is the creation of an awards program for those early career investigators. So we call them the Emerging-Generation Awards, and we also have the Young Physician-Scientist Awards. And these are really to recognize people who are making that transition from being kind of a trainee and a postdoc and have finished their clinical training into becoming an independent assistant professor. And so, those are small awards, but they're kind of a symbolic tap on the shoulder, if you will, that the ASCI sees you, you're talented, stay the course. We want you to become a future member. Don't give up and please keep on fighting. I think that can take us only so far.Anna Greka (42:45):I mean, unless there's a real investment, of course still it will be hard to maintain people in the pipeline. But this is just one way in which we have tried to, these programs that the ASCI offers have been very successful over the last few years. We create a cohort of investigators who are clearly recognized by members of the ASCI is being promising young colleagues. And we give them longitudinal training as part of a cohort where they learn about how to write a grant, how to write a paper, leadership skills, how to run a lab. And they're sort of like a buddy system as well. So they know that they're in it together rather than feeling isolated and struggling to get their careers going. And so, we've seen a lot of success. One way that we measure that is conversion into an ASCI membership. And so, we're encouraged by that, and we hope that the program can continue. And of course, as president, I'm going to be fundraising for that as well, it's part of the role. But it is a really worthy cause because to your point, we have to somehow make sure that our younger colleagues stay the course that we can at least maintain, if not bolster our numbers within the scientific workforce.Eric Topol (43:57):Well, you outlined some really nice strategies and plans. It's a formidable challenge, of course. And we'd like to see billions of dollars to support this. And maybe someday we will because as you say, if we could relieve the financial concerns of people who have curiosity driven ideas.Anna Greka (44:18):Exactly.Eric Topol (44:19):We could do a lot to replenish and build a big physician-scientist workforce. Now, the last thing I want to get to, is you have great communication skills. Obviously, anybody who is listening or watching this.Eric Topol (44:36):Which is another really important part of being a scientist, no less a physician or the hybrid of the two. But I wanted to just go to the backstory because your TED Talk, which has been watched by hundreds of thousands of people, and I'm sure there's hundreds of thousands more that will watch it, but the TED organization is famous for making people come to the place a week ahead. This is Vancouver used to be in LA or Los Angeles area and making them rehearse the talk, rehearse, rehearse, rehearse, which seems crazy. You could train the people there, how to give a talk. Did you have to go through that?Anna Greka (45:21):Not really. I did rehearse once on stage before I actually delivered the talk live. And I was very encouraged by the fact that the TED folks who are of course very well calibrated, said just like that. It's great, just like that.Eric Topol (45:37):That says a lot because a lot of people that do these talks, they have to do it 10 times. So that kind of was another metric. But what I don't like about that is it just because these people almost have to memorize their talks from giving it so much and all this coaching, it comes across kind of stilted and unnatural, and you're just a natural great communicator added to all your other things.Anna Greka (46:03):I think it's interesting. Actually, I would say, if I may, that I credit, of course, I actually think that it's important, for us physician-scientists, again, science and research is a public good, and being able to communicate to the public what it is that we do, I think is kind of an obligation for the fact that we are funded by the public to do this kind of work. And so, I think that's important. And I always wanted to cultivate those communication skills for the benefit of communicating simply and clearly what it is that we do in our labs. But also, I would say as part of my story, I mentioned that I had the opportunity to attend a special school growing up in Greece, Anatolia, which was an American school. One of the interesting things about that is that there was an oratory competition.Anna Greka (46:50):I got very early exposure entering that competition. And if you won the first prize, it was in the kind of ancient Rome way, first among equals, right? And so, that was the prize. And I was lucky to have this early exposure. This is when I was 14, 15, 16 years old, that I was training to give these oratory speeches in front of an audience and sort of compete with other kids who were doing the same. I think these are just wonderful gifts that a school can give a student that have stayed with me for life. And I think that that's a wonderful, yeah, I credit that experience for a lot of my subsequent capabilities in this area.Eric Topol (47:40):Oh, that's fantastic. Well, this has been such an enjoyable conversation, Anna. Did I miss anything that we need to bring up, or do you think we have it covered?Anna Greka (47:50):Not at all. No, this was wonderful, and I thoroughly enjoyed it as well. I'm very honored seeing how many other incredible colleagues you've had on the show. It's just a great honor to be a part of this. So thank you for having me.Eric Topol (48:05):Well, you really are such a great inspiration to all of us in the biomedical community, and we'll be cheering for your continued success and thanks so much for joining today, and I look forward to the next time we get a chance to visit.Anna Greka (48:20):Absolutely. Thank you, Eric.**************************************Thanks for listening, watching or reading Ground Truths. Your subscription is greatly appreciated.If you found this podcast interesting please share it!That makes the work involved in putting these together especially worthwhile.All content on Ground Truths—newsletters, analyses, and podcasts—is free, open-access.Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. And such support is becoming more vital In light of current changes of funding and support for biomedical research at NIH and other US governmental agencies.Thanks to my producer Jessica Nguyen and to Sinjun Balabanoff for audio and video support at Scripps Research. Get full access to Ground Truths at erictopol.substack.com/subscribe

Ten months after the government stipulated guidelines to curb them, dark patterns continue to be used by ecommerce companies in India-from travel to health tech. These deceptive design strategies are used to manipulate users into sharing personal information or making unintended purchases. With India's e-commerce market expected to reach $350 billion by 2030, this is a menace that needs to be prevented. But how? Anirban Chowdhury and Dia Rekhi talk to Manisha Kapoor of ASCI, Nidhi Khare, Consumer Affairs Secretary and Sachin Taparia of LocalCircles to understand the nuances and the way forward. You can listen to our earlier episode by Mugdha Variyar on Why dark patterns are under the surveillance spotlight? ET Podcasts now has a new show. 7@7 is your quick, sharp sub 5 minute daily roundup of financial news from India and the world. Tune in to Apple Podcasts, Spotify, Amazon Prime Music, Jio Saavn, Youtube or wherever you get your podcasts from! Check out other interesting episodes from the host like: Trains to Turbines: How India is Harnessing Hydrogen, Is Bajaj Housing's High Valuation Sustainable?, Corner Office Conversation with Antonoaldo Neves, CEO, Etihad Aviation Group, Has ONDC Managed To Take On Amazon And Flipkart?, and more! You can follow Anirban Chowdhury on his social media: Twitter and Linkedin You can also follow Dia Rekhi on social media: Linkedin & Twitter Catch the latest episode of ‘The Morning Brief' on ET Play, The Economic Times Online, Spotify, Apple Podcasts,JioSaavn, Amazon Music and Youtube.See omnystudio.com/listener for privacy information.

Service Excellence is what defines the credit union movement, but the recent ASCI survey on customer satisfaction begs to differ. In this episode we emphasize the need for maintaining attention to detail and customer satisfaction.   In this episode we cover: Where Chick-fil-A and credit unions are similar. Speed between credit unions and other financial institutions. The evolution of service excellence in the last 10 years What does the future of service excellence look like? How can you be a part of the movement to improve service excellence.   Links from show:   Click here to see American Customer Satisfaction Index to see how credit unions and banks compare today.   Free Resources - watch our leadership minute videos and get our free books to inspire you to give excellent service.   Interested in service excellence? Sign up for our course here.   Subscribe to ServiStar Leadership Podcast on your favorite streaming service.

"Wenn ich das mache, will ich zumindest den Ehrgeiz entwickeln, da der Beste sein zu können", sagt Piran Asci. Er studierte Mathematik und kam 2014 für ein Praktikum zu KoRo Drogerie. Mit 40.000€ aus dem Verkauf von Yu-Gi-Oh! Sammelkarten (Sidehustle während dem Studium) kaufte er ein Jahr später Robert, den Mitgründer von KoRo, raus und führte das Unternehmen zusammen mit Costa auf über 300 Mitarbeiter und mehr als 120 Mio. Umsatz (2023). Im Podcast berichtet er von KoRo's Social Media Power, von Herausforderungen mit Investoren (Social Chain) und verrät➡️ wie sie anfangs von 100.000€ Kapitalbedarf eine Runde über 750.000€ abgeschlossen haben➡️ warum das Kombinieren von Komponenten eine Leistung für sich und darum innovativ genug ist und➡️ wie er das meiste aus einem Arbeitstag von 8 bis 20h herausholt ***Timestamps00:00 - 00:38 Intro00:39 - 01:35 1. Ich bin Piran01:36 - 02:52 2. 10 schnelle Fragen02:53 - 15:00 3. Werdegang15:01 - 17:42 4. Yu-Gi-Oh!-Kartenspiel17:43 - 20:21 5. Strukturierung bei KoRo20:22 - 23:38 6. Vorgeschichte: KoRo Drogerie23:39 - 29:17 7. Wachstumsreise29:18 - 35:24 8. 6-Stelliger Betrag auf dem Konto35:25 - 40:46 9. KoRo heute40:47 - 48:10 10. Inspirationskanäle48:11 - 51:15 11. Investornmanagement51:16 - 56:21 12. Durchschnittswoche56:22 - 58:15 13. PokemonGo-Trick58:16 - 1:02:37 14. Zukunftsvision1:02:38 - 1:05:33 15. Teuflische und himmlische Fragen1:05:34 - Outro***Mehr über Piran:LinkedIn: https://www.linkedin.com/in/piran-asci-3a2043b3/***Weitere Podcast Highlights:- Magdalena Pusch: Jazz-Musikerin, Gründerin, FRAMEN, EXIT an Springerhttps://youtu.be/vmnqQOCmMKA- Felix Leonhardt: Harvard, Food Startup, EXIT, VC Investorhttps://youtu.be/v1nHquV1s5I***Mehr über Startup Schlau:Instagram: https://www.instagram.com/startupschlau/ TikTok: https://www.tiktok.com/@startupschlauund https://startup-schlau.de/

El Faro Camping con Fito Robles, de Siloé, con quien cada jueves iremos de festival en festival. La Ruta Quetzal se creó en 1979 con la finalidad de que los jóvenes recorran lugares de América o Europa siguiendo siempre las huellas de personajes cruciales de la historia de la Comunidad Iberoamericana. ¿Estás aún pensando tus vacaciones? ASCI, la guía especializada europea en campings, ha elegido el Playa Montroig como el Mejor Camping de 2023. Para rematar hemos llamado a Antonia, que cada noche se sale al fresco de la puerta de su casa en Algar, Cádiz, para hablar con sus vecinos. 

The Centre's production-linked incentive, or PLI scheme, which seeks to incentivise manufacturing in India by providing fiscal stimulus, seems to have run into problems. The government is reportedly planning to hold a first-of-its-kind meeting later in June, to address implementation issues being faced by producers under the scheme. Moreover, government sources have indicated that out of the 14 sectors under the scheme, the ones where progress has been sluggish may see a course correction. So, what changes does the PLI scheme need and why?  The detailed analysis and subsequent course correction for the six ‘sluggish sectors' under the PLI scheme would help in better utilisation of fund allocation over the next two to three years. While India Inc is striving to strengthen its industrial base, a significant number of Indian millionaires have been relocating abroad of late. Though the Indian economy is growing at a faster rate and creating more high net worth individuals, the private wealth migration is a matter of concern. So, why are the HNIs leaving India?    Meanwhile, the US Federal Reserve's surprise hawkish pause of interest rate hike spoiled investors' sentiment back home, on Thursday. Domestic benchmark indices slipped up to 0.5% after the US Fed projected two more rate hikes this year. Amid the rising interest rate scenario in global economies, will domestic equities face pressure in the near-term? How should investors navigate this volatility?  The Centre recently announced that it will come up with guidelines for ‘dark patterns' on the internet in the next two months. The ministry of corporate affairs and ASCI met with various stakeholders including Google, Meta and Amazon to discuss these manipulative practices. But what are these ‘dark patterns'? Listen to this episode of the podcast to know more. 

ffodpod.comCC-BY-SA"SCP-378" by UraniumEmpire, from the SCP WikiSource: https://scp-wiki.wikidot.com/scp-378Licensed under CC-BY-SA

The Biden administration is setting a high bar to improve customer experience across government, but the VA's National Cemetery Administration is already at the top of the charts, according to one scorecard.NCA ranks number one among all public and private organizations on the American Customer Satisfaction Index. It's the seventh time NCA has won the top honor, but the latest ranking is the agency's first since the start of the COVID-19 pandemic.Under Secretary for Memorial Affairs Matthew Quinn said in a recent interview with Federal News Network that NCA's top marks from the ASCI, a scorecard released every three years, underscores the agency's commitment to “own the moment” for veterans and their families. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Biden administration is setting a high bar to improve customer experience across government, but the VA's National Cemetery Administration is already at the top of the charts, according to one scorecard. NCA ranks number one among all public and private organizations on the American Customer Satisfaction Index. It's the seventh time NCA has won the top honor, but the latest ranking is the agency's first since the start of the COVID-19 pandemic. Under Secretary for Memorial Affairs Matthew Quinn said in a recent interview with Federal News Network that NCA's top marks from the ASCI, a scorecard released every three years, underscores the agency's commitment to “own the moment” for veterans and their families. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jio vs Star Sports: Ad Inventory yet to be sold - (10:00) - 5G - Postpaid Plan hiked & Rise of ARPU - (16:23) - Why smart phones in 10k range are losing? - (22:00) - Link PAN-Aadhaar before March 31 - (26:45) - The rise of Pre Wedding Photo Shoots - (28:44) - Textile Parks announced by Government - (36:10) - Campa Cola vs Coca Cola : Price Wars - (40:35) - Reliance is working on affordable Cardiac Medicines - (41:40) - AC prices might reduce by 2027 - (53:05) - Trade Deficit narrows down : Is it good or bad? - (54:45) - India's Chief Economic Advisor on Uncertainity - (57:20) - Don't believe anything blindly - (1:02:05) - Classification of Influencers by ASCI - (1:10:32) - Binge Listen to all Note Panra episodes from 1st with this

Mit KoRo CEO Piran Asci. Ob Nussmuse, Großpackungen Haferflocken, oder auch seit neuestem Secco: der Online Händler KoRo hat ein beinahe unendliches Sortiment an haltbaren Lebensmitteln und Food-Enablern. Der Co-Founder und CEO Piran erzählt in der heutigen Folge des New Commerce Podcasts darüber, wie KoRo am laufenden Band neue Produkte launcht (bis zu 500 pro Jahr), und wie sie damit auch neue Märkte erobern. Außerdem geht er darauf ein, wie etwas andere Produktfotos der ultimative Online Shop Hack waren, und was er beim Einsatz von Influencer Marketing am meisten bereut. Danke für diese spannende Folge! Und denkt daran: mit NEWCOMMERCE5 bekommt ihr 5% Rabatt auf das KoRo Sortiment! ____________________ >Piran Asci auf LinkedIn >Jason Modemann auf LinkedIn Fragen, Kommentare oder Wünsche zum Podcast? Schau auf unserer Seite vorbei: www.new-commerce.de/podcast

Guest Introduction - (1:23) . Who do you think an influencer is? - (6:47) . Tech Influencer - P.C Doc - https://www.instagram.com/pcdoc_nanda/?hl=en - (8:32) . Ex. US Navy Seal Jockowillink - https://www.instagram.com/jockowillink/?hl=en - (10:39) . Why did you start this Insta page? - (11:20) . Do influencers do promotions based on taraget audience & brand attributes while promoting? - (14:00) . Do influencers taker responsibiliy checking thier audience attrbutes - (17:00) . Deepika V Influencer - https://www.instagram.com/deepika_v__/?hl=en - (17:40) . Sample Deck used for Brand Deal's - https://docs.google.com/presentation/d/1mZXOr2BvuVA0r8x965wMntx2rb9Ii34jhz-rEq597t0/edit?usp=sharing . Why influencers turn off comments section in brand promotions? - (20:11) . Who buys these fake followers accounts? - (22:39) . Tamilselvi Influencer - https://www.instagram.com/thamizhselvi_/?hl=en - (23:32) . Sugi Vijay - https://www.instagram.com/_sugivijay_/?hl=en - (23:42) . Who has upper hand in dictating terms Businesses or Influencers? - (29:08) . Hote room bookings by influencers - (30:58) . Food Influencers - (34:06) . The problem with our judicial system - (36:39) . ASCI complaint by Cat - (38:05) . Thr rise of Demat Accounts - (39:41) . PR Sundar & Fintech Influencers - (39:04) . E-Commerce MLM's - (42:17) . Crypto investments loss - (43:37) . Sensible Verification Company - (46:25) . Stock Market metrics to measure - (47:16) . Are influencer aware of financial losses by their followers? - (50:17) . Do small businesses know about other marketing channels other than Influencer Marketing? - (51:18) . The problem with Digital Marketing Agencies - (52:38) . Jason's e-commerce startup Mercemur (rebranded to Zemuria) : https://zemuria.com/?utm_source=podcast&utm_medium=audio&utm_campaign=mms - (53:02) . The criteria to be onboarded by Zemuria (previously known as Mercemur) - (56:54) . Mercemur's Market Expansion to foreign countries - (59:08) . Indian Managers in foreign countries - (1:01:38) . How some digital marketing agencies are operating today? - (1:05:15) . Jason's advice and suggestions to small business owners - (1:07:17) . Zemuria's Extended Marketing Service - (1:20:35) . Interview trends in TN Youtube Channels - (1:23:19) . Cat's Mangatha daww entry - (1:29:11) . Changes Jason wishes to see from Influencer's side - (1:29:55) . Mama Earth's IPO - (1:38:21) . Just another startup in TN - (1:39:22) . How Corporate Layoffs happen - (1:47:05) . Jason's end note to listeners - (1:52:10) . Jason's Insta profile link - https://www.instagram.com/thejasonsamuel/?hl=en . Do let us know your feednack and suggestions about this episode... we'll be back with another banger episode with Jason Samuel.. stay tuned! --- Send in a voice message: https://podcasters.spotify.com/pod/show/mba-meme-school/message

Aaj k episode main baat karenge ASCI guidelines k updates k baare main aur Influencers kya bol rahe hai uske baare main.Janne k liye sunte rahiye Namastey India!

Unser heutiger Gast hat Mathematik an der freien Universität Berlin studiert und 2015 mit einem Bachelor und 2017 mit einem Master of Science abgeschlossen. 2014 gewann er mit seinem Team den Funpreneur-Wettbewerb der Freien Universität Berlin, spätestens seitdem begeistert ihn das Unternehmertum. Seit 2014 arbeitet er bei KoRo und er hat sich dort in sehr kurzer Zeit vom begeisterten Kunden über den Werkstudenten zum CEO entwickelt. Zusammen mit einem Co-Founder kaufte er 2016 die Seed-Investoren raus und das Unternehmen entwickelt sich seit dem sehr dynamisch weiter. Uns ist KoRo als aktiver Werbepartner diverser Podcastformate aufgefallen und wir sind bei New Work Masterskills seit einiger Zeit begeisterte Kunden. Es bleibt nur eine Frage offen? Warum macht Ihr keine Werbung bei uns? Seit mehr als 5 Jahren beschäftigen wir uns mit der Frage, wie Arbeit den Menschen stärkt - statt ihn zu schwächen. In 350 Gesprächen haben wir mit mehr als 400 Menschen darüber gesprochen, was sich für sie geändert hat und was sich weiter ändern muss. Wir sind uns ganz sicher, dass es gerade jetzt wichtig ist, Arbeit qualitativ zu verbessern. Denn die Idee von “New Work” wurde während einer echten Krise entwickelt. Sie ist nicht für eine Bubble gedacht, sondern für uns alle. Wie gehen Start-Ups und Scale-Ups in wirtschaftlich schweren Zeiten vor, und was können wir von ihnen lernen. Wir suchen nach Methoden, Vorbildern, Erfahrungen, Tools und Ideen, die uns dem Kern von New Work näher bringen! Darüber hinaus beschäftigt uns auch diese Woche immer noch die Frage, ob wirklich alle Menschen das finden und leben können, was sie im Innersten wirklich, wirklich wollen. Ihr seid bei On the Way to New Work - heute mit Piran Asci. Episode 350 gibt es auf allen gängigen Podcast-Plattformen, wie Spotify oder Apple Podcasts (oder direkt auf otwtnw.de). Einfach nach ‘On the Way to New Work' suchen und abonnieren, um keine Folge zu verpassen. Christoph und Michael veröffentlichen immer montags um 6:00 Uhr.

Have you tried crossing out an irritating ad while reading an article online, but the 'cross' is almost invisible or the ad itself refuses to go away? Well, you've encountered a dark pattern. Vani speaks with Manisha Kapoor about dark patterns, why you must be aware of how you as a consumer might be manipulated, and what you can do better as an advertiser to not win the consumer's ire!

'Dark patterns' are deceptive practices that try to influence consumer behaviour. Self-regulatory body ASCI is also looking at guidelines for data privacy, says CEO Manisha Kapoor.

The advertising world has been a male-dominated one for a very long time. Though we have come a long way but still if we would switch on the television today, we would see women protagonists playing gender-stereotypical roles. Today on Filter Koffee Podcast, Karthik is joined by Manisha Kapoor, CEO & Secretary General of the Advertising Standards Council of India (ASCI). ASCI is an organization set up by industry stakeholders to regulate itself. Karthik and Manisha talk about self-regulation in the industry, the guidelines that the organization has put out for the influencers, and some interesting pushback from the brands that ASCI has observed. Sit with your coffee, because your sports experience is about to change! This and much more are only on the Filter Koffee Podcast!—Listen to this conversation and don't forget to rate us on Spotify and Apple Podcasts! Tweet to Karthik Nagarajan (@The_Karthik): https://twitter.com/The_Karthik and follow his WordPress handle here (filterkoffee.com).You can listen to this and other incredible shows on the IVM Podcasts app on Android: https://ivm.today/android or iOS: https://ivm.today/ios, or any other podcast app.You can check out our website at http://www.ivmpodcasts.com

In the next installment of ASTCT's Titans of Transplant series, Dr. John. F. DiPersio, an internationally recognized leader in hematopoietic stem cell transplantation and acute leukemia and past president of ASTCT (2019) is interviewed by Dr. Roman Shapiro. About Dr. John F. DiPersio John F. DiPersio, MD, PhD is deputy director at Alvin J. Siteman Cancer Center, director at Center for Gene and Cellular Immunotherapy and chief of the division of oncology at Washington University School of Medicine in St. Louis and the Virginia E. and Samuel J. Golman professor of medicine. His research focuses on mechanistic and translational aspects of leukemia and stem cell biology. He has played a key role in the clinical development of plerixafor as a mobilizing agent for stem cell transplantation. DiPersio has played a key leadership role in the team-science work at Washington University that has defined the genetic and epigenetic factors that contribute to clonal evolution and relapse in AML. He has served in leadership roles for the American Society of Hematology (ASH), multiple NIH, CIRM, LLS, and CPRIT Study Sections, and has served on NCI's Board of Scientific Counselors. He is an elected member of ASCI and AAP, and past president of the American Society of Transplantation and Cellular Therapy (2019). About Dr. Roman Shapiro Roman Shapiro, MD is a physician working with the bone marrow transplantation group at the Dana-Farber Cancer Institute. His main clinical and academic interest is the prevention and treatment of malignant disease following stem cell transplant. His contributions to science include optimizing the use of natural killer (NK) cell therapy, including cytokine-induced memory-like (CIML) NK cells, for the prevention and treatment of post-transplant relapse of myeloid disease. The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nurses, social workers and more who were on the frontlines of the early days of transplant.

Piran Asci ist ein echtes Arbeitstier. Seine Firma - die Lebensmittel-Drogerie KoRo - leitet er unbändig und bis ins Detail herein. Wie schafft er es dabei, dass seine Work-Life-Balance nicht total aus dem Ruder läuft? Im Gespräch mit Joel erzählt der CEO, wie sein üblicher Arbeitstag aussieht, was er in seiner Zeit bei KoRo (auch mal schmerzhaft) über Führung gelernt hat und wie er es schafft, sich Raum für Hobbies, Beziehung und Freunde zu lassen. Du erfährst… • …wieso Pirans Weg zu KoRo einige Umwege hatte • …wie die Beziehung zu seinem Vater Pirans Geschäfts-Ethos geprägt hat • …wie ein Tag im Leben von Piran Asci aussieht • …woran Piran erkennt, welche Entscheidung er delegieren kann

Aaj k episode me baat karenge ASCI ki guidelines breach k baare main.Kyun nhi follow ho rahi ye guidelines?Janne k liye sunte rahiye Namastey India!

Eigentlich wollte Piran Asci nur eine Provision bekommen, wenn er die Produkte von KoRo weiterempfiehlt - dann ist er Geschäftsführer des Lebensmittelunternehmens geworden. Wie das passiert ist und warum Yu-Gi-Oh!-Karten dabei entscheidend waren, erzählt er im Gespräch mit Janna. Er redet auch über die Erfolgsformel von KoRo: Zehn Jahre nach Gründung ist die Marke nämlich für ihre nachhaltigen Produkte in Großverpackungen bekannt, gerade bei Influencern sehr beliebt, im Sortiment von manchen Supermärkten zu finden und in 18 europäischen Ländern vertreten. Und er spricht ganz offen darüber, warum die nachhaltigsten Produkte nicht immer diejenigen sind, die am nachhaltigsten aussehen und warum noch viel Aufklärungsarbeit bei den Kunden sowie bei den Investoren geleistet werden muss. +++Eine Produktion der Audio Alliance.Host: Janna LinkeRedaktion: Lucile Gagnière und Nicole PlichProduktion: Lia Wittfeld +++Jetzt BUSINESS PUNK-Abo flexibel mit kostenloser Ausgabe testen unter business-punk.com/gratis +++Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

It's that time of year when you have to brace yourself for yet another episode of covid! Yes, covid is back and so are masks. In other e vents, Layer'r was shot by netizens, the government, and ASCI over the weekend. Both of the controversial advertisements that promote rape culture as a joke have been removed. Tune in to know more about this!

KoRo Drogerie ist die Anlaufstelle für Nüsse, Superfoods und Dattel-Haselnuss-Creme für den täglichen Porridge. Erst vor kurzem konnte das Berliner Food-Startup ein Investment von 50 Millionen gewinnen. Das achtstellige Investment soll in die Internationalisierung und Vergrößerung der Produktpalette reinvestiert werden, um dieses Jahr ein Umsatzziel von 100 Millionen zu knacken. Wie und warum KoRo namenhafte Investoren wie Mario Götze oder Philipp Westermeyer gewinnen konnte, erzählt Gründer und CEO Piran Asci in dieser Folge. Außerdem wollen wir von ihm wissen, wie KoRo den amerikanischen Markt erschließen möchte, welche Rolle das Influencer Marketing heute bei KoRo spielt und wie letzendlich ein erfolgreicher Influencer-Deal aussieht. Kleiner Hinweis: Diese Folge wurde im Metaverse aufgenommen! Wie Piran diese Erfahrung wahrgenommen hat und wie sich das anhört? Jetzt reinhören! Fragen und Feedback zum Podcast? Schreibt uns

Julie interviewt Mehmet.

Here are the top cryptocurrency news headlines from India this week:India's crypto investors spooked by the market pullback triggered by the Russian invasion of Ukraine: https://economictimes.indiatimes.com/tech/technology/spectre-of-crypto-winter-spooks-all/articleshow/89806536.cms ;ASCI releases advertising guidelines for crypto: https://www.coindesk.com/policy/2022/02/23/indias-crypto-advertising-guidelines-are-out/ ;Supreme Court asks the government to clarify its stance on crypto: https://timesofindia.indiatimes.com/india/is-bitcoin-trading-legal-or-illegal-sc-asks-govt/articleshow/89838013.cms ;Indian banks have still not warmed up to crypto transactions: https://www.deccanherald.com/business/business-news/indian-banks-yet-to-warm-up-to-crypto-transactions-1084802.html ;Indian exchanges shifting base to crypto-friendly jurisdictions such as UAE and Singapore: https://www.ndtv.com/business/how-uae-and-singapore-are-turning-into-crypto-hubs-withindian-exchanges-moving-base-2784664 ;IAMAI holds NFT conference: https://www.coindesk.com/markets/2022/02/24/first-mover-asia-india-crypto-firms-regulators-continue-their-regulatory-debate-bitcoin-recovers-from-a-post-invasion-freefall/ ;Infosys launches Infosys Metaverse Foundry: https://www.prnewswire.com/in/news-releases/launching-infosys-metaverse-foundry-service-to-accelerate-enterprises-ability-to-evolve-and-execute-strategies-for-virtual-physical-interconnections-814663769.html ;Airtel acquires stake in blockchain startup Aqilliz: https://www.dqindia.com/airtel-acquires-strategic-stake-in-blockchain-technology-startup-aqilliz/ ;US-based blockchain firm Cion Digital to expand in India: https://www.dqindia.com/us-based-saas-blockchain-cion-digital-to-expand-in-india/ ;Nagpur police seizes assets worth Rs 40 crore in connection to a crypto scam: https://inc42.com/buzz/nagpur-police-seizes-assets-worth-inr-40-cr-in-crypto-scam-duping-2k-investors/ ;New Crypto Scams in India: https://coincrunch.in/2022/02/21/new-day-new-crypto-scams-in-india/ ;WazirX to release tools for entrepreneurs to build their own cryptocurrency exchanges;Zebpay lists 22 new tokens in its INR market through its QuickTrade feature;

NSE co-location probe explained Reliance takes the shortcut mode to clinch Future Group Unacademy launches cricket courses with Sachin Government planning to tax processed fat foods Why crypto is taxed high in India? ASCI regulation for Crypto and NFT's along with other business news and marketing insights from Feb 21 to 27 presented to you by Cat and Robo. --- Send in a voice message: https://anchor.fm/mba-meme-school/message

Aaj k episode me baat karenge Crypto advertisements se related policy and guidelines k baare main.Kya sahi hai kya galat hai, batayenge aaj k episode par.Sunte rahiye Namastey India!

On this inaugural episode of the CEO Roundtable Podcast, we're chatting with Daniel G Abrego, CEO of ACSI Tech. Dan has been in the telecommunications business nearly 20 years, 10 of those years as CEO. As a company, ASCI provides telecommunications services to some of the biggest names in internet service. As an influential organization, it's changing the way companies should think about their employees.  For Dan, that thought originated out of compassion for the struggles that those in his industry are accustomed to. “Unfortunately they live check to check and if their car breaks down or something, you know, we deal with some contractors, we have our own in-house employees and I find myself offering some loans or whatnot. We decided to implement ACSI dream foundation and part of the goal is to teach everything about telecom from modern day technology from cryptocurrency and NFTs; for everyone of all ages. The key component, is that unlike traditional higher education organizations, Dan hopes to be able to offer employment upon completion of their programs. And as that thought progressed, on how he could help his employees, another idea came to Dan which prompted another company to be born: Buschman Entertainment. A nickname from his drinking days, when a six pack of Busch Beer would cost only three bucks, he went with it and hasn't looked back since.  “If we hire you, we allow you five hours to yourself to do what you want to do and help you and spearhead that initiative, whether it be in music or other creative initiatives. So, we built a little studio in our warehouse, and my son who more recently got his degree in audio engineering will  help produce some of their music. Then, being honest with them, if we feel like they're good we'll continue that initiative. If they're the only ones that feel that they're good, then we'll say ‘Maybe you should consider something else.'” Another component of how Dan looks out for his employees is their health and wellness. While still providing the traditional medical benefits one would come to expect, he also offers his employees something less traditional, too.  “If you don't, you don't prioritize the wellness of your employees. They're just not going to perform physically or mentally. What I did was offer non-traditional Eastern medicine. You can get acupuncture, massage, you want to take your kids or yourself to karate martial arts, you can do that. We bought the program and the employee is only required to pay 50%.” Tune in to hear more on this unique approach to creating a culture that promotes creativity and wellness as a priority for its employees. 

Influencer marketing has become an essential part of the digital marketing mix!In this episode, Vani speaks with Subhash Kamath, Chairman and Manisha Kapoor, Secretary-General of The Advertising Standards Council of India, who explains the ASCI guidelines for Influencer Marketing and why it is required.

Aaj k episode me baat karenge ASCI guidelines k breach k baare main aur kon kon se influencers isme pakde gaye aur kya kaarwaahi hui aage.Sunte rahiye Namastey India!

I started Beyond Philosophy 20 years ago when Customer Experience was the next big thing; the new concept that was going to change everything in business. The last big thing, Customer Relationship Management (CRM), was old news. After all, everyone had one at that point.  Now, in 2022, I see the next big thing: Customer Science. Customer Science combines the power of artificial intelligence (AI), customer data, and the concepts of behavioral science to help organizations create a winning customer strategy. Leveraging the power of Customer Science, organizations can understand why their customers are doing what they are now and, perhaps more importantly, what they are likely to do next.  In this episode, we talk about Customer Science and how it can turn things around for your organization in 2022. Will you be on this new wave of change's crest or left in its trough making the same mistakes you did last year? Key Ideas to Improve your Customer Experience The mistakes of last year are best summarized by lagging or plateauing Customer Satisfaction Scores. The American Customer Satisfaction Index (ACSI) says only 30 percent of companies tracked by ACSI improved their score over the last 10 years. Another way to look at it is ASCI says 70 percent of companies either had flat results or saw a decline in customer satisfaction. All this to say, it's time for a next level for customer strategy. As Customer Experience moves aside for Customer Science, we have found it. Here are a few key moments in the discussion: 03:21  Colin describes how what he is seeing in business today regarding customer experience feels familiar to what was happening over two decades ago with CRM. 08:34  We get into what Customer Science is and what it is capable of doing for businesses today.   13:27  Colin reads some articles for 2002 regarding CRM, when experiences were becoming a new focus and compares it to what is happening with Customer Experience today.     20:10  Colin explains what this might mean for Customer Experience professionals moving forward with the new wave of change. 22:51 We share how to respond to these changes in the best possible way for your organization and your career as we move into 2022.      Please tell us how we are doing! Complete this short survey.  Customer Experience Information & Resources LinkedIn recognizes Colin Shaw as one of the 'World's Top 150 Business Influencers.' As a result, he has 289,000 followers of his work. Shaw is Founder and CEO of Beyond Philosophy LLC, which helps organizations unlock growth by discovering customers' hidden, unmet needs that drive value ($). The Financial Times selected Beyond Philosophy LLC as one of the best management consultancies for the last two years. Follow Colin on LinkedIn and Twitter. Click here to learn more about Professor Ryan Hamilton of Emory University.  Why Customers Buy: As an official "Influencer" on LinkedIn, Colin writes a regular newsletter on all things Customer Experience. Click here to join the other 22,000 subscribers.  Experience Health Check: You already have an experience, even if you weren't deliberate about it. Our Experience Health Check can help you understand what you have today. Colin or one of our team can assess your digital or physical Customer Experience, interacting with your organization as a customer to define what is good and what needs improving. Then, they will provide a list of recommendations for critical next steps for your organization. Click here to learn more.  How can we help? Click here to learn more about Beyond Philosophy's Suite of Services.

I started Beyond Philosophy 20 years ago when Customer Experience was the next big thing; the new concept that was going to change everything in business. The last big thing, Customer Relationship Management (CRM), was old news. After all, everyone had one at that point.  Now, in 2022, I see the next big thing: Customer Science. Customer Science combines the power of artificial intelligence (AI), customer data, and the concepts of behavioral science to help organizations create a winning customer strategy. Leveraging the power of Customer Science, organizations can understand why their customers are doing what they are now and, perhaps more importantly, what they are likely to do next.  In this episode, we talk about Customer Science and how it can turn things around for your organization in 2022. Will you be on this new wave of change's crest or left in its trough making the same mistakes you did last year? Key Ideas to Improve your Customer Experience The mistakes of last year are best summarized by lagging or plateauing Customer Satisfaction Scores. The American Customer Satisfaction Index (ACSI) says only 30 percent of companies tracked by ACSI improved their score over the last 10 years. Another way to look at it is ASCI says 70 percent of companies either had flat results or saw a decline in customer satisfaction. All this to say, it's time for a next level for customer strategy. As Customer Experience moves aside for Customer Science, we have found it. Here are a few key moments in the discussion: 03:21  Colin describes how what he is seeing in business today regarding customer experience feels familiar to what was happening over two decades ago with CRM. 08:34  We get into what Customer Science is and what it is capable of doing for businesses today.   13:27  Colin reads some articles for 2002 regarding CRM, when experiences were becoming a new focus and compares it to what is happening with Customer Experience today.     20:10  Colin explains what this might mean for Customer Experience professionals moving forward with the new wave of change. 22:51 We share how to respond to these changes in the best possible way for your organization and your career as we move into 2022.      Please tell us how we are doing! Complete this short survey.  Customer Experience Information & Resources LinkedIn recognizes Colin Shaw as one of the 'World's Top 150 Business Influencers.' As a result, he has 289,000 followers of his work. Shaw is Founder and CEO of Beyond Philosophy LLC, which helps organizations unlock growth by discovering customers' hidden, unmet needs that drive value ($). The Financial Times selected Beyond Philosophy LLC as one of the best management consultancies for the last two years. Follow Colin on LinkedIn and Twitter. Click here to learn more about Professor Ryan Hamilton of Emory University.  Why Customers Buy: As an official "Influencer" on LinkedIn, Colin writes a regular newsletter on all things Customer Experience. Click here to join the other 22,000 subscribers.  Experience Health Check: You already have an experience, even if you weren't deliberate about it. Our Experience Health Check can help you understand what you have today. Colin or one of our team can assess your digital or physical Customer Experience, interacting with your organization as a customer to define what is good and what needs improving. Then, they will provide a list of recommendations for critical next steps for your organization. Click here to learn more.  How can we help? Click here to learn more about Beyond Philosophy's Suite of Services.

On Cyrus Says today, Cyrus is Joined by Suchita Salwan and Varun Duggirala, hosts of the 'Think Fast' podcast. They talk about how they started the podcast and the idea behind it, what the conversation on the podcast are like, how they have never met each other other than over video call, and lots more. They also talk about Suchita working with Wizcraft, Varun's upcoming book 'Everything is Out of Syllabus' and what its about, and both the guests share stories of launching of LBB and The Glitch. They also discuss the qualities they like about each other, and what both would change about the other. Further, Suchita gives us her views on why Elon Musk is being persuaded by many states in India to come and invest, what Varun has to say on ASCI's study of what Indians find 'offensive', and more. Tune in for an amazing episode. Follow 'Think Fast" Podcast on website: https://shows.ivmpodcasts.com/show/think-fast-with-varun-and-suchita-j3rd-R1TlLHtCesjirRuv Check out Varun Duggirala's upcoming book https://www.amazon.in/Everything-Out-Syllabus-Instruction-Manual/dp/0143455028 You can follow Varun Duggirala on Twitter at: https://twitter.com/varunduggi and on Instagram at https://instagram.com/varunduggi Follow Suchita Salwan on Twitter at https://twitter.com/suchitasalwan and on Instagram at https://instagram.com/suchitasalwan Subscribe to our new YouTube channel: https://www.youtube.com/channel/UCmY4iMGgEa49b7-NH94p1BQ Also, subscribe to Cyrus' YouTube channel: https://youtube.com/channel/UCHAb9jLYk0TwkWsCxom4q8A You can follow Amit on Instagram & Twitter @DoshiAmit: https://twitter.com/doshiamit and https://instagram.com/doshiamit You can follow Antariksh on Instagram @antariksht: https://instagram.com/antariksht Do send in AMA questions for Cyrus by tweeting them to @cyrussaysin or e-mailing them at whatcyrussays@gmail.com Don't forget to follow Cyrus Broacha on Instagram @BoredBroacha (https://www.instagram.com/boredbroacha) In case you're late to the party and want to catch up on previous episodes of Cyrus Says you can do so at: www.ivmpodcasts.com/cyrussays You can listen to this show and other awesome shows on the new and improved IVM Podcasts App on Android: https://ivm.today/android or iOS: https://ivm.today/ios

It's Cock and Bull time!! Cyrus rants about visiting cards going out of fashion, whether Amit ever had fancy designations on his business cards, and Silverie and Amit take a little revenge on Cyrus by presenting previous Words-of-the-week from previous epiodes to see how many Cyrus actually remembers. Also, what's with Antariksh and the Grand Center connection? Why do restaurants charge for 'chakna'? Further, they also discuss ASCI's study about what Indians find 'offensive' in ads. Also, Cyrus answers some AMAs about the The Beatles 'Get Back' Documentary, if Cyrus can be our Ben Shapiro, and movies that can be watched again and again and again. Tune in for this and much more. Subscribe to our new YouTube channel: https://www.youtube.com/channel/UCmY4iMGgEa49b7-NH94p1BQ Also, subscribe to Cyrus' YouTube channel: https://youtube.com/channel/UCHAb9jLYk0TwkWsCxom4q8A You can follow Amit on Instagram & Twitter @DoshiAmit: https://twitter.com/doshiamit and https://instagram.com/doshiamit You can follow Antariksh on Instagram @antariksht: https://instagram.com/antariksht Do send in AMA questions for Cyrus by tweeting them to @cyrussaysin or e-mailing them at whatcyrussays@gmail.com Don't forget to follow Cyrus Broacha on Instagram @BoredBroacha (https://www.instagram.com/boredbroacha) In case you're late to the party and want to catch up on previous episodes of Cyrus Says you can do so at: www.ivmpodcasts.com/cyrussays You can listen to this show and other awesome shows on the new and improved IVM Podcasts App on Android: https://ivm.today/android or iOS: https://ivm.today/ios

Here are the top cryptocurrency news headlines from India this week:India's cryptocurrency bill likely to be ready only by May: https://www.coindesk.com/policy/2021/12/23/indias-crypto-law-might-not-be-ready-before-may-sources-say/ ;India ends Winter Session of Parliament with no crypto bill in sight: https://www.businessinsider.in/cryptocurrency/news/no-india-crypto-bill-in-sight-even-after-winter-session-of-parliament-comes-to-a-close/articleshow/88449161.cms ;Crypto bill likely to ask exchanges to appoint a grievance officer: https://www.businessinsider.in/cryptocurrency/news/india-may-ask-crypto-exchanges-to-appoint-grievance-officers-in-crypto-bill/articleshow/88384965.cms ;RBI flags concerns on stablecoins: https://economictimes.indiatimes.com/tech/technology/rbi-raises-fresh-concerns-over-stablecoins/articleshow/88460294.cms?from=mdr ;Narcotics Control Bureau getting trained in crypto: https://coincrunch.in/2021/12/22/india-parliamentary-updates-on-crypto-delhi-courts-summon/ ;Code of conduct for crypto ads coming soon: https://www.thehindubusinessline.com/money-and-banking/cryptocurrency/crypto-ads-self-regulation-guidelines-likely-to-be-out-soon/article38025971.ece ;Big 4 ask employees to disclose crypto investments: https://economictimes.indiatimes.com/industry/services/consultancy-/-audit/big-4-ask-employees-to-disclose-this-years-crypto-investments/articleshow/88499412.cms ;IIT Kharagpur invites applications for free online course on blockchain technology: https://www.telegraphindia.com/edugraph/news/iit-kharagpur-invites-applications-for-free-online-course-on-blockchain-technology/cid/1844368 ;WazirX lists Ooki Protocol (OOKI), Beam (BEAM), Mobox (MBOX), Request (REQ) and QuickSwap (QUICK);Zebpay lists Solana (SOL) in its INR market;Bitbns lists MYNE token in its INR market;

Did you know that customer satisfaction scores are the lowest they have been in the past 15 years? It's true, and you can't blame it all on COVID, although there is some blame to be cast there. Per the American Customer Satisfaction Index (ACSI), only 30 percent of companies tracked by ASCI improved their score; that means 70 percent didn't, and that's alarming. It's also one of seven significant lessons that 2021 taught us.  This new year also coincides with the 20th anniversary of me founding my global Customer Experience Consultancy, Beyond Philosophy and publishing my first book on the subject, Building Great Customer Experiences (Palgrave Macmillan, 2002). Things have changed since then, but one thing that hasn't is that people want exceptional experiences that meet (or exceed) their expectations—and organizations need to deliver them. In this episode, we explore the seven things we learned professionally and personally in 2021 and what they mean for your customer strategy in 2022. Spoiler alert: it means that everything is changing. Again. Key Ideas to Improve your Customer Experience Twenty years ago, all the signs around me pointed to the next big thing in business: Customer Experience. However, the influence of Customer Experience is waning now, making way for something new: Customer Science. Customer Science is the blend of Artificial Intelligence, customer data, and the behavioral sciences, and just like its predecessor Customer Experience, it has outstanding implications for your customer strategy.  Here are a few key moments in the discussion: 04:52   Ryan kicks off the professional lessons learned this year with the realization that changing challenges is the reality of the business environment today and how to respond to it.  06:43  Colin explains how uncertainty is something human beings do not process well, and it leads to customer behavior that reflects the behavioral science theory of Loss Aversion.  10:26  Colin explains that Customer Experience is getting absorbed into a larger, more influential concept poised to change the business world, Customer Science.   12:45  Colin shares shocking statistics from the American Customer Satisfaction Institute Index.     15:06   Ryan and Colin discuss what is happening to Customer Experience and how it is the cycle of things in business.  17:05  Colin explains how some companies succeeded in improving their customer satisfactions scores. 19:03  Ryan shares that his personal learning in 2021 was about work/life balance and that he thinks little improvements in areas of his life lead to more improvements down the road.    22:10  Colin talks about his weight loss journey and how a jolt to his bad habits in his personal life demonstrates what often needs to happen in the business world.      Please tell us how we are doing! Complete this short survey.  Customer Experience Information & Resources LinkedIn recognizes Colin Shaw as one of the 'World's Top 150 Business Influencers.' As a result, he has 289,000 followers of his work. Shaw is Founder and CEO of Beyond Philosophy LLC, which helps organizations unlock growth by discovering customers' hidden, unmet needs that drive value ($). The Financial Times selected Beyond Philosophy LLC as one of the best management consultancies for the last two years. Follow Colin on LinkedIn and Twitter. Click here to learn more about Professor Ryan Hamilton of Emory University.  Why Customers Buy: As an official "Influencer" on LinkedIn, Colin writes a regular newsletter on all things Customer Experience. Click here to join the other 22,000 subscribers.  Experience Health Check: You already have an experience, even if you weren't deliberate about it. Our Experience Health Check can help you understand what you have today. Colin or one of our team can assess your digital or physical Customer Experience, interacting with your organization as a customer to define what is good and what needs improving. Then, they will provide a list of recommendations for critical next steps for your organization. Click here to learn more.  How can we help? Click here to learn more about Beyond Philosophy's Suite of Services.

Did you know that customer satisfaction scores are the lowest they have been in the past 15 years? It's true, and you can't blame it all on COVID, although there is some blame to be cast there. Per the American Customer Satisfaction Index (ACSI), only 30 percent of companies tracked by ASCI improved their score; that means 70 percent didn't, and that's alarming. It's also one of seven significant lessons that 2021 taught us.  This new year also coincides with the 20th anniversary of me founding my global Customer Experience Consultancy, Beyond Philosophy and publishing my first book on the subject, Building Great Customer Experiences (Palgrave Macmillan, 2002). Things have changed since then, but one thing that hasn't is that people want exceptional experiences that meet (or exceed) their expectations—and organizations need to deliver them. In this episode, we explore the seven things we learned professionally and personally in 2021 and what they mean for your customer strategy in 2022. Spoiler alert: it means that everything is changing. Again. Key Ideas to Improve your Customer Experience Twenty years ago, all the signs around me pointed to the next big thing in business: Customer Experience. However, the influence of Customer Experience is waning now, making way for something new: Customer Science. Customer Science is the blend of Artificial Intelligence, customer data, and the behavioral sciences, and just like its predecessor Customer Experience, it has outstanding implications for your customer strategy.  Here are a few key moments in the discussion: 04:52   Ryan kicks off the professional lessons learned this year with the realization that changing challenges is the reality of the business environment today and how to respond to it.  06:43  Colin explains how uncertainty is something human beings do not process well, and it leads to customer behavior that reflects the behavioral science theory of Loss Aversion.  10:26  Colin explains that Customer Experience is getting absorbed into a larger, more influential concept poised to change the business world, Customer Science.   12:45  Colin shares shocking statistics from the American Customer Satisfaction Institute Index.     15:06   Ryan and Colin discuss what is happening to Customer Experience and how it is the cycle of things in business.  17:05  Colin explains how some companies succeeded in improving their customer satisfactions scores. 19:03  Ryan shares that his personal learning in 2021 was about work/life balance and that he thinks little improvements in areas of his life lead to more improvements down the road.    22:10  Colin talks about his weight loss journey and how a jolt to his bad habits in his personal life demonstrates what often needs to happen in the business world.      Please tell us how we are doing! Complete this short survey.  Customer Experience Information & Resources LinkedIn recognizes Colin Shaw as one of the 'World's Top 150 Business Influencers.' As a result, he has 289,000 followers of his work. Shaw is Founder and CEO of Beyond Philosophy LLC, which helps organizations unlock growth by discovering customers' hidden, unmet needs that drive value ($). The Financial Times selected Beyond Philosophy LLC as one of the best management consultancies for the last two years. Follow Colin on LinkedIn and Twitter. Click here to learn more about Professor Ryan Hamilton of Emory University.  Why Customers Buy: As an official "Influencer" on LinkedIn, Colin writes a regular newsletter on all things Customer Experience. Click here to join the other 22,000 subscribers.  Experience Health Check: You already have an experience, even if you weren't deliberate about it. Our Experience Health Check can help you understand what you have today. Colin or one of our team can assess your digital or physical Customer Experience, interacting with your organization as a customer to define what is good and what needs improving. Then, they will provide a list of recommendations for critical next steps for your organization. Click here to learn more.  How can we help? Click here to learn more about Beyond Philosophy's Suite of Services.

Here are the top cryptocurrency news headlines from India this week:Finance Minister Nirmala Sitharaman clarifies that India's Cryptocurrency Bill is not the same as the previous version: https://coincrunch.in/2021/11/30/new-crypto-bill-finance-minister/ ;ASCI In Talks With Government Over Cryptocurrency Advertising: https://inc42.com/buzz/asci-in-talks-with-government-over-cryptocurrency-advertising/ ;SEBI likely to regulate the crypto industry in India: https://www.ndtv.com/business/all-private-cryptocurrency-will-be-regulated-not-banned-sources-2634414 ;India's new crypto law set to red-flag chit fund, MLM business models: https://economictimes.indiatimes.com/industry/banking/finance/banking/indias-new-crypto-law-set-to-red-flag-chit-fund-mlm-business-models/articleshow/88040313.cms ;Cryptocurrencies may be added to existing tax laws: https://economictimes.indiatimes.com/news/economy/finance/govt-looking-to-add-cryptocurrencies-to-tax-law/articleshow/88082435.cms ;Mukesh Ambani hails India's effort to introduce the cryptocurrency bill: https://indianexpress.com/article/technology/crypto/cryptocurrency-bill-india-mukesh-ambani-7654621/ ;Ministry of Electronics and Information Technology releases National Strategy on Blockchain: https://www.business-standard.com/article/economy-policy/meity-proposes-national-blockchain-strategy-for-adoption-across-sectors-121120400047_1.html ;Silicon Valley's Draper Dragon Fund makes India debut: https://economictimes.indiatimes.com/tech/funding/silicon-valley-crypto-fund-draper-dragon-eyes-india-debut/articleshow/87990727.cms ;Navi Mutual Fund files for blockchain fund: https://www.moneycontrol.com/news/business/personal-finance/sachin-bansal-backed-navi-mutual-fund-files-for-blockchain-fund-7787941.html ;Fintech startup Defy raises $5.5 million to build a social crypto exchange: https://www.livemint.com/market/cryptocurrency/defy-raises-5-5-mn-launches-india-s-first-social-crypto-exchange-11637232872411.html ;CoinDCX plans to pursue IPO as soon as India regulations are in place: https://economictimes.indiatimes.com/tech/startups/coindcx-plans-to-pursue-ipo-as-soon-as-india-regulations-are-in-place/articleshow/87975836.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst ;CoinDCX is Not Doing an IPO Anytime Soon: https://coincrunch.in/2021/11/29/coindcx-is-not-doing-an-ipo-anytime-soon/ ;WazirX list Tranchess (CHESS), Cocos-BCX (COCOS), Gifto (GTO) and Gala Games (GALA);Bitbns lists bePAY's native token beCOIN;Zebpay lists The Sandbox (SAND) token in its INR and USDT market;

On this episode, Cyrus is joined by Manisha Kapoor, Secretary-General at Advertising Standards Council of India (ASCI), to talk about ASCI's Gender Next study, and lots more. They talk about how Manisha got into advertising, her working for Hindustan Unilever and Johnson & Johnson, among other brands, how she got into ASCI, the aim of the GenderNext study, trying to move the gender disparities in entertainment and ads, the need to reflect the new journeys that women are going through, how advertising can help make life more aspirational for women, progressive ways to show modern couples, why tropes in ads can be problematic, how these biases exist in both men and women due to years of conditioning, and tons more.Manisha also talks about the trolling that brands sometimes face when trying to be progressive, the functions of the ASCI, indirect alcohol marketing that alcohol brands do in India, and more.Follow Manisha on LinkedIn: https://www.linkedin.com/in/manisha-kapoor-04a5a81Subscribe to our new YouTube channel: https://www.youtube.com/channel/UCmY4iMGgEa49b7-NH94p1BQAlso, subscribe to Cyrus' YouTube channel: https://youtube.com/channel/UCHAb9jLYk0TwkWsCxom4q8AYou can follow Antariksh on Instagram @antariksht: https://instagram.com/antarikshtDo send in AMA questions for Cyrus by tweeting them to @cyrussaysin or e-mailing them at whatcyrussays@gmail.comDon't forget to follow Cyrus Broacha on Instagram @BoredBroacha (https://www.instagram.com/boredbroacha)In case you're late to the party and want to catch up on previous episodes of Cyrus Says you can do so at: www.ivmpodcasts.com/cyrussaysYou can listen to this show and other awesome shows on the new and improved IVM Podcasts App on Android: https://ivm.today/android or iOS: https://ivm.today/ios

Amitabh Bachchan recently pulled out of an endorsement deal with a popular pan masala brand on his 79th birthday after facing a backlash on social media. The Bollywood megastar, who featured in the ad for this brand's ‘silver-coated cardamom seeds' with actor Ranveer Singh, claimed that he was not aware when the ad was being filmed that it fell under surrogate advertising. He also returned the money he had received for the endorsement. This was not the first time an actor had landed in such a controversy. In 2016, former James Bond actor Pierce Brosnan had appeared in a surrogate advertisement for another pan masala manufacturer. He had claimed that the company cheated him by not disclosing the harmful nature of its product. The company, on the other hand, stressed that the product Brosnan endorsed was a mouth freshener and should not be associated with chewing tobacco.  Several actors, including Shah Rukh Khan, Ajay Devgn, Mahesh Babu, Salman Khan, Anushka Sharma, Priyanka Chopra, Tiger Shroff and Hrithik Roshan, have also made appearances in the ads of mouth fresheners made by pan masala brands.  India's pan masala market size*  2020: Rs 45,585 crore 2026: Rs 69,518 crore  *Projections by IMARC Group According to market research firm IMARC Group, the size of the pan masala market in India, which was Rs 45,585 crore in 2020, is projected to reach Rs 69,518 by 2026.  Amitabh Bachhan's pullout has reignited a debate on the legality of such ads. Companies use surrogate advertising as a workaround to promote tobacco and alcohol products, whose advertising is banned by law in the country.  But how are celebrities able to promote such brands? It is done through what is called surrogate advertising. Surrogate advertising first surfaced in India after the Cable Television Networks (Regulation) Act 1995 banned direct advertisements of liquor, cigarettes and tobacco products.  Such ads promote the established brand names of companies whose main products fall under the category whose advertising is not allowed. This is done by using the same brand names for different products altogether. The purpose of surrogate ads is to increase brand recall in the minds of consumers. New products carrying the same brand name are known as brand extensions, which is not illegal under the Act. The rules allow some liberty for such surrogate advertisements under the pretext of brand extensions. Notable examples include the ads for soda and music CDs by liquor companies. This is done using trademark diversification.   The Cigarettes and Other Tobacco Products Act (COTPA) 2003 prohibits direct and indirect advertising of tobacco products. This Act also does not allow ads of other goods using the brand name of tobacco products. But plain pan masala that does not contain tobacco can be advertised on television, even though its packaging contains a mandatory health warning, since it has ingredients like betel nut, a known carcinogen that is addictive.  But celebrities are restricted from advertising plain pan masala because of explicit Advertising and Standards Council of India guidelines, which say that products bearing health warnings by law cannot be endorsed by them. Nonetheless, ads for cardamom seeds, such as those done by Amitabh Bachhan and Hrithin Roshan, are seen as surrogate for tobacco products or pan masala bearing the same brand name. Established in 1985, the ASCI is a voluntary self-regulatory organisation with members from marketing, media, and allied companies. It has laid out the criteria for what constitutes a genuine brand extension and not a surrogate advertisement for tobacco and liquor products.  In January this year, it banned surrogate ads of 12 liquor companies after they failed to convince these were genuine extensions.  In May this year, ASCI issued strict guidelines to crack down on surrogate ads. The rules state that the product sold under the brand extension that has been p

Aaj k episode me baat karenge ASCI ki influencer guidelines k baare main. Kuch updates and violations jo aapko pata honi chahiye. Ye ek update episode hai. Janne k liye sunte rahiye Namastey IndiaVOTE for Namastey India -Click here -> Hubhopper Awards 2021Select Category -> Best News & politics podcastEnter Your EmailSelect Namastey India from the dropdownClick on VOTE!VOTE for Socially Desi -Click here -> Hubhopper Awards 2021Select Category -> Best Business & Entrepreneurship podcastEnter Your EmailSelect The Socially Desi Show from the dropdownClick on VOTE!Iss bar jeetna hai guys aap he ka award hai ... Ghar laana hai. Sunte rahiye Namastey India

Wafik El-Deiry, MD, PhD, FACP, is Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Director, Cancer Center at Brown University, practicing oncologist and ACS Professor. El-Deiry earned MD/PhD degrees at U. Miami, completed Medicine residency, Oncology fellowship at Johns Hopkins where he discovered CDK-inhibitor p21WAF1. He was HHMI Investigator, tenured Professor of Medicine, Genetics and Pharmacology, Associate Director for Physician-Scientist Training in Hem-Onc, and Radiobiology Program leader at Penn's Abramson Cancer Center. He was Chief of Hem-Onc at Penn State, and Deputy Director at Fox Chase Cancer Center. Dr. El-Deiry discovered TRAIL death receptor DR5, TRAIL-Inducing Compound #10 (TIC10), and founded Oncoceutics to bring TIC10/ONC201 to patients where it showed exceptional responses against glioblastoma. He has >400 publications, 5-edited books, H-Index of 120 with > 83,000 citations in Google Scholar. He is an ASCI, AAP member, Past President of Interurban Clinical Club (2013-2014), and Elected Member of Johns Hopkins Society of Scholars (2014). He won the Michael Brown Award (Penn), the Elizabeth and John Cox Award (Georgetown), and the International Kuwait Prize for Cancer. Dr. El-Deiry trained many students, fellows, physician-scientists, and continues to mentor scientists and faculty in basic and translational cancer research. Dr. El-Deiry is one of the original physician-scientists on social media who was recognized among the top 10 Oncologists in the world for impact on Twitter in 2021. Follow him @weldeiry “If you try 10 things and one of them works, you'll be successful.” From naming the WAF1 gene as an oncology fellow to becoming one of the most cited researchers in oncology, Dr. El-Deiry shares with us his unique journey in the space of cancer research. Join us as he shares anecdotes from his early career, overcoming rejections and developing a persistent yet agile mindset to make his mark in medicine. Pearls of Wisdom: 1. If you limit yourself to one attempt and fail, you will think of yourself as a failure. Try your hand at ten things. If you succeed at even one of them, then you are successful. 2. There's a fine line between believing in what you do and understanding the limitations of your idea. That's when you can decide to continue being persistent or decide to be agile and open to change. 3. Finding the right mentor is crucial. What separates a good mentee from a great mentee is their drive to keep trying different things and perpetually reaching out to their mentor to find the right answer.

Subscribe to the Cryptocurrency India Weekly newsletter: https://www.getrevue.co/profile/thecryptodostHere are the top cryptocurrency news headlines from India this week:CoinDCX exchange may become a unicorn soon: https://economictimes.indiatimes.com/tech/funding/coindcx-in-talks-to-raise-100-120-million/articleshow/84840176.cms ;Equalisation levy on crypto exchanges in India will not apply to investors: https://www.businessinsider.in/cryptocurrency/news/the-indian-government-has-no-data-on-how-many-crypto-exchanges-and-investors-working-on-cryptocurrency/articleshow/84821709.cms ;Binance in Regulatory Crosshairs: https://www.livemint.com/market/cryptocurrency/binance-india-summons-executives-of-world-s-largest-crypto-exchange-11627632235407.html ;Indian Crypto exchanges will have new advertisement guidelines soon: https://www.businessinsider.in/cryptocurrency/news/wazirx-coindcx-and-other-indian-crypto-exchanges-will-reportedly-have-new-advertisement-guidelines-in-the-next-seven-to-ten-days/articleshow/84756896.cms ;Non Fungible Tokens gaining traction in India: https://www.livemint.com/technology/tech-news/nft-adoption-gaining-traction-in-india-11627233964069.html ;ICICI, Axis and HDFC Bank buy stake in blockchain Startup IBBIC: https://www.livemint.com/companies/news/sbi-kotak-axis-hdfc-icici-bank-pick-up-stake-in-blockchain-platform-ibbic-11627390888288.html ;Votechain launches blockchain-based online voting platform EazyVC: https://www.expresscomputer.in/news/votechain-launches-eazyvc-indias-blockchain-based-online-voting-platform/77910/ ;Binance launches new tax reporting tool: https://www.financialexpress.com/money/income-tax/binance-launches-tax-reporting-tool-how-will-it-help-indian-crypto-investors-in-income-tax-return-filing/2300077/ ;FOHO Coin IEO goes live on the Bitbns;WazirX completes 5th Quarterly WRX Burn: https://blog.wazirx.com/wazirx-completes-5th-quarterly-wrx-burn/ ;Zebpay lists 10 tokens in its USDT market;CoinSwitch Kuber enables limit orders for all coins;

Anfangs zeigte sich der Unternehmergeist von Piran Asci, wenn es um sein Lieblingskartenspiel "Yu-Gi-Oh!" ging. Er kaufte und verkaufte Karten, um sich etwas dazu zu verdienen. Wie ihm das half, relativ jung vom Werkstudenten zum CEO von KoRo zu werden, erzählt er im OMR Podcast. Die Themen des Podcasts mit Koro-CEO Piran Asci: Piran Asci ist nicht der Gründer von Koro. Wie ging die Geschichte des Unternehmens los? Und wie wurde Asci vom Werkstudenten zum CEO? (04:41) Wie entwickelt sich das Geschäft von Koro? (06:58) Was Koro anders macht als der Wettbewerb (07:51) 1.000 Produkte und ein überraschender Top-Seller (11:44) Mit Youtube und Instagram gewachsen (13:19) Wie das Influencer Marketing von Koro funktioniert (16:51) Der Start einer Offline-Strategie (22:46) Wie die Zusammenarbeit mit dem Handel läuft (26:56) Würde Piran Asci auch Amazon-Händler kaufen? (30:00) Wie Georg Kofler bei Koro eingestiegen ist (32:17) Die Content-Strategie von Koro (35:45) Wie sieht die Internationalisierungs-Strategie aus? (37:58) Ärgert sich Piran Asci, dass er die Mehrheit am Unternehmen abgegeben hat? (40:42) Welche Produktideen hat Piran Asci noch im Schrank? (43:46) Wie Koro seine Eigenmarken produziert (48:26) Wie sieht die Koro-Zielgruppe aus? (49:50) Koro hat jetzt ein Abo-Modell. So funktioniert es (51:01) So legt Koro seine Preise fest (54:46) Warum man den Shop des Unternehmens nachkaufen kann (56:01) In der Zeit der Creator Economy: Plant Koro gemeinsame Produkte mit Influencern? (58:36)

One Take Show is honoured to host Ms. Ankita Singh. Ms. Singh is the co-founding partner at A&P Partners, which is a full-service law firm based in Mumbai. Ms. Singh has experience advising domestic as well as international clients on matters regarding litigation and dispute resolution. She specializes in the field of intellectual property rights, sports, media & entertainment law. Her firm A&P Partners has been enlisted in the Forbes Legal Powerlist 2020 as one of the top law firms in IP practice. Ms. Singh is an alumnus of ILS Law College, Pune. She has been actively handling and appearing in various litigation matters pertaining to disputes in respect of IPR and has successfully managed to procure notable and benchmark orders from various Courts including the Hon'ble High Court of Bombay. Ms. Singh has managed to procure a benchmark-setting order influencing laws globally- to state a few in the matter of ‘Kross Television India Pvt. Ltd. & Anr. Vs. Vikhyat Chitra Productions & Ors' communication via Whatsapp messenger and data reflected by the mobile application to be accepted as proof of service of summons is a precedent set by her firm. The said order was a first of its kind and set a precedent, which has been later followed across the country and even globally including Singapore. Pursuant thereto, Ankita has been involved in various other noteworthy matters and continues to do so. In addition to representing production houses, media houses, individual artists before various forums across India and even internationally, Ms. Singh has advised extensively on trademark laws, copyright, designs law and their registration at various jurisdictions domestically and internationally. She has also advised on media and entertainment-related negotiations and disputes including those of Production Agreements, Distributorship Agreements, Advertising Agreements, Remake Agreements, Artist Agreement, Directors Agreement etc. Ms. Singh holds expertise in IPR laws and dispute resolution in general and has regularly been invited to impart guest lectures/ workshops by corporates. Link to the Article: https://www.helpdesq.in/asci-guidelines-for-influencers/

Here are the resources that were mentioned in the podcast.  https://covidlonghaulers.com/wp-content/uploads/2021/06/Persistence-of-SARS-CoV-2-S1-Protein-in-CD16-Monocytes-in-Post-Acute-Sequelae-of-COVID-19-PASC-Up-to-15-Months.pdf https://www.frontiersin.org/articles/10.3389/fimmu.2021.700782/full https://longcovidalliance.org/tag/covid-19-longhauler-advocacy-project/ https://docs.google.com/document/u/0/d/1VfENjAiOBKryT-dIOFyU8CyEAAKVR5xk9WyvlZF-u4M/mobilebasic https://covidlonghaulers.com/wp-content/uploads/2021/03/SARS-CoV-2-Viral-RNA-Shedding-for-More-Than-87-Days....Cd8T-Cell.pdf https://covidlonghaulers.com/wp-content/uploads/2021/06/ASCI-1st-Quarter-2021-Article-The-Need-for-Precision-Medicin-in-Active-Post-COVID-19.pdf --- Send in a voice message: https://anchor.fm/the-real-mommas-of-modoc/message

Tune into this engaging conversation we had with Dr. Falguni Vasavada-Oza, Professor & Chair, Strategic Marketing area at MICA. As advertising is a volatile field, let us engage in an insightful conversation talking about how New-Age Advertising is shaping the industry today, giving rise to Influencer Marketing and various Social Media Strategies. Hear her talk about, if Advertising is going to die out in the near future (04:56), the new ASCI guidelines and its impact on the influencer marketing industry (08:20), should brands rely on human instincts and intelligence for decision making (11:28) and much more! #MICASTOvertime #MICA #SchoolofIdeas #Podacst #BusinessPodcast #Marketingmaniac #SocialMedia #DigitalStrategy #WorldofAvertising #NewAgeAdvertising #DecisionMaking

With the growth of digital media, we have seen an upsurge in influencer marketing. With the new ASCI guidelines, what will influencer-generated content look like? How are brands responding to this change? What does it take to follow one's passion and convert it into a profession- and what this means to an influencer producing content of his/her interest. In a very interesting conversation with Kamiya Jani, Founder of Curly Tales, India's leading Food & Travel platform with over 4 mn followers, this episode highlights the importance of influencer marketing. A Small Note: The last year or more has been a tough one for all of us. And the second wave of COVID-19 has been much worse. To help those affected by the pandemic in India, the podcasting community has come together under the #PodForChange banner to raise funds through an exclusive NGO partner, Give India. Join Ep.Log and #PODFORCHANGE as we look to make a positive impact in the lives of those affected by COVID19. Please visit the link: tinyurl.com/PodForChangeIndia. Remember, someone really needs the help. You can follow us and leave us feedback on Facebook, Instagram, and Twitter @eplogmedia, For advertising/partnerships send you can send us an email at bonjour@eplog.media. If you like this show, please subscribe and leave us a review wherever you get your podcasts, so other people can find us. You can also find us on https://www.eplog.media DISCLAIMER: The views expressed on all the shows produced and distributed by Ep.Log Media are personal to the host and the guest of the shows respectively and with no intention to harm the sentiments of any individual/organization.The said content is not obscene or blasphemous or defamatory of any event and/or person deceased or alive or in contempt of court or breach of contract or breach of privilege, or in violation of any provisions of the statute, nor hurt the sentiments of any religious groups/ person/government/non-government authorities and/or breach or be against any declared public policy of any nation or state.See omnystudio.com/listener for privacy information.

Spricht man mit Piran Asci, einem der drei Geschäftsführer von KoRo Drogerie, merkt man sofort, dass in dem Food Onlinehändler nicht nur viele innovative Ideen stecken, sondern auch viel Mut und Durchhaltevermögen. Wie KoRo von anfänglichen Startschwierigkeiten zu mittlerweile über 20 Millionen Umsatz kam und wieso das breite und diverse Sortiment der größte Wachstumshebel ist, erklärt der sehr sympathische und offene Berliner im ChefTreff-Interview mit Sven Rittau. In der Folge mit Sven und Piran lernst Du:

Ein Podcast-Gast auf den der Future Food Club viel zu lange warten musste: Piran Asci, Mitgründer und CEO bei KoRo Drogerie, ist einer der großen deutschen Namen in der Natural-Food- & E-Commerce-Welt. KoRo bietet hochwertige natürliche Food-Produkte in Großpackungen und hat so ein Millionenbusiness aufgebaut, das schnell weiter wächst. Doch das lässt das Team um Piran und Kosta nicht ruhen - eine eigene Eisdiele in Berlin-Mitte sowie ein revolutionärer Lieferdienst sind schon in Planung. Hört rein!